Printer Friendly

AMGEN CONFIRMS COURT FILING

 AMGEN CONFIRMS COURT FILING
 THOUSAND OAKS, Calif., Jan. 17 /PRNewswire/ -- Amgen Inc.


(NASDAQ National Market System: AMGN) today confirmed that the Company filed a complaint for Declaratory Judgment of Patent Non-Infringement, Invalidity, and Unenforceability against Chugai Pharmaceutical, Co., Ltd. (Chugai) in respect to certain U.S. patents issued to Chugai relating to granulocyte colony-stimulating factor (G-CSF). In addition, the complaint alleges violation of 18 U.S.C., sections 1961 et. seq., and common law fraud. The complaint was filed today in the U.S. District Court for the District of Columbia.
 Amgen is seeking a declaratory judgment by the U.S. District Court that certain Chugai patents are not infringed by Amgen and are invalid and unenforceable.
 Amgen is an international pharmaceutical company that develops, manufactures and markets human therapeutics based on advanced cellular and molecular biology.
 -0- 1/17/92
 /CONTACT: Sarah H. Crampton, 805-499-5725, ext 3250 (office) 805-499-4727 (home), or Kimberly L. Dorsey, 805-499-5725, ext 4367 (office) 805-373-6161 (home), both of Amgen/
 (AMGN) CO: Amgen Inc. ST: California IN: MTC SU:


CH -- LA020 -- 1172 01/17/92 17:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 17, 1992
Words:182
Previous Article:McDONNELL DOUGLAS RECEIVES A $14.7 MILLION CONTRACT FOR RECERTIFICATIONS OF U.S. NAVY TOMAHAWK SEA-LAUNCHED CRUISE MISSILES
Next Article:THE TORONTO STOCK EXCHANGE MARKET CLOSING
Topics:


Related Articles
Transkaryotic and Hoechst move to reopen gene-activated erythropoietin litigation in district court.
TKT updates status of erythropoietin litigation.
TKT announces victory over Amgen in Dynepo.
Court Dismisses Amgen Reimbursement Challenge.
AMGEN PROFITS SOAR NEWER DRUGS FUEL SURGE.
AMGEN SUES OVER EPOGEN THREE UNITS OF ROCHE ACCUSED OF PATENT INFRINGEMENT.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters